monocyte membrane-coated nanoparticles (MoNP)-Verteporfin (VP) treatment alleviated the TNFalpha-induced inflammatory response in Endothelial cells
Atherosclerosis, characterized by the buildup of plaque in arteries, is a major cause of cardiovascular mortality worldwide, as there is no efficient strategy for targeted therapy. However, we have developed a new drug delivery platform called MoNP, which is loaded with VP, a potent inhibitor of YAP/TAZ signaling. To investigate the MoNP-VP treatment effect, EC were pretreated with MoNP or MoNP-VP then induced the inflammation by TNFalpha. After TNFalpha treatment, the cells were collected and extracted the RNA for RNA sequencing (RNA-Seq). The results showed that MoNP-VP significantly decreased the expression of YAP/TAZ-targeted genes and inflammatory markers while upregulating atheroprotective genes. Overall, these findings suggest that MoNP-VP has the potential to serve as an effective drug delivery platform for atherosclerosis.